中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

19 records (took 0.026 seconds)

    METHODS FOR DETECTING TH1 CELLS
    15.
    发明申请
    METHODS FOR DETECTING TH1 CELLS 有权

    公开(公告)号：US20130231466A1

    公开(公告)日：2013-09-05

    申请号：US13840851

    申请日：2013-03-15

    Applicant: EISAI R&D MANAGEMENT CO., LTD.

    Inventor： Keiko Yamaguchi ,  Toshio Imai ,  Kenzo Muramoto

    IPC: C07K16/28

    CPC classification number: C07K16/18 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/76 ,  G01N33/56972 ,  G01N2333/075 ,  G01N2333/085

    Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

    BIOMARKER FOR RHEUMATOID ARTHRITIS TREATMENT
    16.
    发明申请
    BIOMARKER FOR RHEUMATOID ARTHRITIS TREATMENT 有权

    公开(公告)号：US20220205980A1

    公开(公告)日：2022-06-30

    申请号：US17601908

    申请日：2020-04-20

    Applicant: EISAI R&D MANAGEMENT CO., LTD.

    Inventor： Nobuyuki Yasuda ,  Tomohiro Yamada ,  Fumitoshi Tago ,  Seiichiro Hojo ,  Toshio Imai

    IPC: G01N33/50 ,  C07K16/24 ,  A61P19/02

    Abstract: An object of the present invention is to provide a method for predicting a therapeutic effect of a drug that inhibits FKN-CX3CR1 interaction on rheumatoid arthritis in a rheumatoid arthritis subject, and novel and more effective therapeutic agent for rheumatoid arthritis exploiting the method. In order to predict a therapeutic effect of a drug that inhibits fractalkine (FKN)-CX3CR1 interaction in a rheumatoid arthritis subject, provided is a method comprising predicting the therapeutic effect of the drug in the subject on the basis of a measurement value of CD16+ monocytes in a biological sample obtained from the subject before the start of administration of the drug.

    Methods for detecting Th1 cells
    18.
    发明授权
    Methods for detecting Th1 cells 有权
    检测Th1细胞的方法

    公开(公告)号：US09175073B2

    公开(公告)日：2015-11-03

    申请号：US13840927

    申请日：2013-03-15

    Applicant: Eisai R&D Management Co., Ltd.

    Inventor： Keiko Yamaguchi ,  Toshio Imai ,  Kenzo Muramoto

    IPC: C07K16/00 ,  C07K16/46 ,  C07K16/24 ,  C07K16/18 ,  C07K16/28 ,  G01N33/569

    CPC classification number: C07K16/18 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/76 ,  G01N33/56972 ,  G01N2333/075 ,  G01N2333/085

    Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

    Abstract translation: 本发明人发现已知局限在细胞内粘附位点的粘附分子CAR用作活化淋巴细胞的粘附分子。 此外，本发明人鉴定了CARL，一种在淋巴细胞中表达的新型CAR配体，并阐明了配体在Th1细胞中有选择性表达。 此外，他们发现抗CAR抗体可以抑制活化淋巴细胞对CAR分子的粘附。 因此，本发明提供了使用CAR或抗CARL抗体检测Th1细胞的方法，以及使用CAR和CARL之间的结合作为指标筛选抑制Th1细胞粘附的抑制剂的方法。 此外，本发明涉及筛选CAR和CARL之间的结合抑制剂的方法，抑制CAR和CARL之间的结合的抗体以及包含这些抗体的治疗组合物。 预期这些可用于诊断涉及Th1细胞浸润的疾病，例如炎症，以及提供减轻这些疾病的药物。

    METHODS FOR DETECTING TH1 CELLS
    19.
    发明申请
    METHODS FOR DETECTING TH1 CELLS 有权

    公开(公告)号：US20130230523A1

    公开(公告)日：2013-09-05

    申请号：US13840927

    申请日：2013-03-15

    Applicant: EISAI R&D MANAGEMENT CO., LTD.

    Inventor： Keiko Yamaguchi ,  Toshio Imai ,  Kenzo Muramoto

    IPC: C07K16/28

    CPC classification number: C07K16/18 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/76 ,  G01N33/56972 ,  G01N2333/075 ,  G01N2333/085

    Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies. These are expected to be useful in diagnosing diseases, such as inflammation, in which infiltration of Th1 cells is involved, and in providing pharmaceutical agents for alleviating such diseases.

Patent Agency Ranking